News
RedHill Biopharmas opaganib shows activity against Covid-19 variants
RedHill Biopharma has reported initial findings from a preclinical study, which revealed that its drug candidate, opaganib (Yeliva, ABC294640), could block Covid-19 variants of...
News
Lonza Invests CHF 20 million to Expand API Development and Manufacturing Facility in Nansha, China
Lonza announced new investments in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China. The investments, totaling over CHF...
Press Releases
Roche’s Actemra/RoActemra receives U.S. FDA EUA for the treatment of COVID-19 in hospitalised adults and children
Roche announced that the U.S. FDA has issued an EUA for intravenous Actemra/RoActemra® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric...
Clinical Trials
CluePoints Launch Post-COVID Trial Assurance Solution
CluePoints, the premier provider of Risk-Based Quality Management Solutions for clinical trials, has launched a new Post-COVID Trial Assurance Solution as part of its mission...
News
Building authentication eco-systems is crucial to prevent falsified medicines; must implement export measures for domestic market : Experts at The Authentication Forum webinar
Held on 11 June, ASPA and Messe Frankfurt India united senior leaders and industry experts for a panel discussion on “Protecting the lives and...
News
Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of Induced Pluripotent Stem Cell-based Therapies
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products,...
Drug Research
Roches Actemra/RoActemra receives U.S. FDA EUA for the treatment of COVID-19 in hospitalised adults and children
Roche announced that the U.S. FDA has issued an EUA for intravenous Actemra/RoActemra® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read